Pheochromocytoma and paraganglioma: imaging characteristics
Juan Carlos Báez(Brigham and Women's Hospital), Nikhil H. Ramaiya(Brigham and Women's Hospital), Katherine Zukotynski(McMaster University), Katherine M. Krajewski(Brigham and Women's Hospital), Kevin O′Regan(Brigham and Women's Hospital), Jyothi P. Jagannathan(Brigham and Women's Hospital), Matthew H. Kulke(Brigham and Women's Hospital)
Cited by 66
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
|Journal of Clinical Oncology|2018|388
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
|Journal of Clinical Oncology|2012|301
Pneumatosis Intestinalis and Bowel Perforation Associated With Molecular Targeted Therapy: An Emerging Problem and the Role of Radiologists in Its Management
|American Journal of Roentgenology|2012|109